A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study

被引：148

作者：

Miyawaki, Shuichi ^{[1
]}

Ohtake, Shigeki ^{[2
]}

Fujisawa, Shin ^{[3
]}

Kiyoi, Hitoshi ^{[4
]}

Shinagawa, Katsuji ^{[5
]}

Usui, Noriko ^{[6
]}

Sakura, Toru ^{[1
]}

Miyamura, Koichi ^{[7
]}

Nakaseko, Chiaki ^{[8
]}

Miyazaki, Yasushi ^{[9
,10
]}

Fujieda, Atsushi ^{[11
]}

Nagai, Tadashi ^{[12
]}

Yamane, Takahisa ^{[13
]}

Taniwaki, Masafumi ^{[14
]}

Takahashi, Masatomo ^{[15
]}

Yagasaki, Fumiharu ^{[16
]}

Kimura, Yukihiko ^{[17
]}

Asou, Norio ^{[18
]}

Sakamaki, Hisashi ^{[19
]}

Handa, Hiroshi ^{[20
]}

Honda, Sumihisa ^{[21
]}

Ohnishi, Kazunori ^{[22
]}

Naoe, Tomoki ^{[4
]}

Ohno, Ryuzo ^{[23
]}

机构：

[1] Saiseikai Maebashi Hosp, Leukemia Res Ctr, Maebashi, Gunma, Japan

[2] Kanazawa Univ, Grad Sch Med Sci, Dept Clin Lab Sci, Kanazawa, Ishikawa, Japan

[3] Yokohama City Univ, Dept Hematol, Med Ctr, Yokohama, Kanagawa 232, Japan

[4] Nagoya Univ, Grad Sch Med, Dept Hematol & Oncol, Nagoya, Aichi 4648601, Japan

[5] Okayama Univ Hosp, Div Hematol Oncol, Okayama, Japan

[6] Jikei Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol, Tokyo, Japan

[7] Japanese Red Cross Nagoya First Hosp, Dept Internal Med, Nagoya, Aichi, Japan

[8] Chiba Univ Hosp, Dept Hematol, Chiba, Japan

[9] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Dept Hematol, Nagasaki 852, Japan

[10] Nagasaki Univ, Grad Sch Biomed Sci, Atom Bomb Dis Inst, Mol Med Unit, Nagasaki 852, Japan

[11] Mie Univ, Grad Sch Med, Dept Hematol & Oncol, Tsu, Mie 514, Japan

[12] Jichi Med Univ, Div Hematol, Shimotsuke, Japan

[13] Osaka City Univ, Dept Hematol, Osaka 558, Japan

[14] Kyoto Prefectural Univ Med, Dept Clin Mol Genet & Lab Med, Kyoto, Japan

[15] St Marianna Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol, Kawasaki, Kanagawa, Japan

[16] Saitama Med Sch, Dept Hematol, Hidaka, Japan

[17] Tokyo Med Univ, Dept Internal Med 1, Div Hematol, Tokyo, Japan

[18] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 860, Japan

[19] Tokyo Metropolitan Komagome Hosp, Dept Hematol, Tokyo, Japan

[20] Gunma Univ, Grad Sch Med, Dept Med & Clin Sci, Maebashi, Gunma 371, Japan

[21] Nagasaki Univ, Grad Sch Biomed Sci, Dept Publ Hlth, Nagasaki 852, Japan

[22] Hamamatsu Univ Sch Med, Ctr Oncol, Hamamatsu, Shizuoka 4313192, Japan

[23] Aichi Canc Ctr, Nagoya, Aichi 464, Japan

来源：

BLOOD | 2011年 / 117卷 / 08期

关键词：

MAINTENANCE INTENSIFICATION THERAPY; INDIVIDUALIZED INDUCTION THERAPY; CONSOLIDATION THERAPY; CYTOSINE-ARABINOSIDE; REMISSION DURATION; KIT MUTATIONS; DAUNORUBICIN; IDARUBICIN; TRIAL; CANCER;

D O I：

10.1182/blood-2010-07-295279

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We conducted a prospective randomized study to assess the optimal postremission therapy for adult acute myeloid leukemia in patients younger than 65 years in the first complete remission. A total of 781 patients in complete remission were randomly assigned to receive consolidation chemotherapy of either 3 courses of high-dose cytarabine (HiDAC, 2 g/m(2) twice daily for 5 days) alone or 4 courses of conventional standard-dose multiagent chemotherapy (CT) established in the previous JALSG AML97 study. Five-year disease-free survival was 43% for the HiDAC group and 39% for the multiagent CT group (P = .724), and 5-year overall survival was 58% and 56%, respectively (P = .954). Among the favorable cytogenetic risk group (n = 218), 5-year diseasefree survival was 57% for HiDAC and 39% for multiagent CT (P = .050), and 5-year overall survival was 75% and 66%, respectively (P = .174). In the HiDAC group, the nadir of leukocyte counts was lower, and the duration of leukocyte less than 1.0 x 10(9)/L longer, and the frequency of documented infections higher. The present study demonstrated that the multiagent CT regimen is as effective as our HiDAC regimen for consolidation. Our HiDAC regimen resulted in a beneficial effect on disease-free survival only in the favorable cytogenetic leukemia group. This trial was registered at www.umin.ac.jp/ctr/as #C000000157. (Blood. 2011;117(8):2366-2372)

引用

页码：2366 / 2372

页数：7

共 29 条

[1]

[Anonymous], 1998, Br J Haematol, V103, P100

[2]

BERMAN E, 1991, BLOOD, V77, P1666

[3]

Bloomfield CD, 1998, CANCER RES, V58, P4173

[4] 6-thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML):: A randomized trial of the German AML cooperative group [J].

Büchner, T ;

Hiddemann, W ;

Berdel, WE ;

Wörmann, B ;

Schoch, C ;

Fonatsch, C ;

Löffler, H ;

Haferlach, T ;

Ludwig, WD ;

Maschmeyer, G ;

Staib, P ;

Aul, C ;

Grüneisen, A ;

Lengfelder, E ;

Frickhofen, N ;

Kern, W ;

Serve, HL ;

Mesters, RM ;

Sauerland, MC ;

Heinecke, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4496-4504

[5] The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: Results of the UK MRC AML 10 trial [J].

Burnett, AK ;

Wheatley, K ;

Goldstone, AH ;

Stevens, RF ;

Hann, IM ;

Rees, JHK ;

Harrison, G .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 118 (02) :385-400

[6]

Burnett AK, 2009, BLOOD, V114, P200

[7] Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study [J].

Cairoli, R ;

Beghini, A ;

Grillo, G ;

Nadali, G ;

Elice, F ;

Ripamonti, CB ;

Colapietro, P ;

Nichelatti, M ;

Pezzetti, L ;

Lunghi, M ;

Cuneo, A ;

Viola, A ;

Ferrara, F ;

Lazzarino, M ;

Rodeghiero, F ;

Pizzolo, G ;

Larizza, L ;

Morra, E .

BLOOD, 2006, 107 (09) :3463-3468

[8] MAINTENANCE CHEMOTHERAPY PROLONGS REMISSION DURATION IN ADULT ACUTE NONLYMPHOCYTIC LEUKEMIA [J].

CASSILETH, PA ;

HARRINGTON, DP ;

HINES, JD ;

OKEN, MM ;

MAZZA, JJ ;

MCGLAVE, P ;

BENNETT, JM ;

OCONNELL, MJ .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :583-587

[9] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia [J].

Cheson, BD ;

Bennett, JM ;

Kopecky, KJ ;

Büchner, T ;

Willman, CL ;

Estey, EH ;

Schiffer, CA ;

Döhner, H ;

Tallman, MS ;

Lister, TA ;

LoCocco, F ;

Willemze, R ;

Biondi, A ;

Hiddemann, W ;

Larson, RA ;

Löwenberg, B ;

Sanz, MA ;

Head, DR ;

Ohno, R ;

Bloomfield, CD .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) :4642-4649

[10] The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].

Grimwade, D ;

Walker, H ;

Oliver, F ;

Wheatley, K ;

Harrison, C ;

Harrison, G ;

Rees, J ;

Hann, I ;

Stevens, R ;

Burnett, A ;

Goldstone, A .

BLOOD, 1998, 92 (07) :2322-2333

← 1 2 3 →